Introduction {#s1}
============

Diabetes is a disorder of glucose homeostasis that results from relative or absolute deficiency of insulin. In type 2 diabetes, a state of tissue insulin resistance prevails, and insulin-producing β-cells are unable to secrete sufficient insulin to overcome this resistance ([@B1]). By contrast, type 1 diabetes (T1D) is characterized by autoimmune-targeted destruction of β-cells, resulting in a state of absolute insulin deficiency ([@B2]). Whereas orally bioavailable small molecules have been developed and approved to prevent or treat type 2 diabetes, no such agents have been introduced to prevent or reverse the β-cell destruction seen in T1D. A challenge in the development of pharmacotherapies for T1D is the identification of specific pathways and targets that contribute to aggressive immune responses and/or β-cell death. Appreciation is increasing for oxidative stress and associated pathways within the β-cell that may predispose the β-cell to death upon activation of autoimmunity in T1D ([@B3]--[@B5]).

12/15-Lipoxygenase (12/15-LOX) is an enzyme encoded by the *Alox15* gene whose eicosanoid products contribute to inflammatory responses in macrophages and β-cells in the setting of diabetes ([@B6]). In mice, 12/15-LOX catalyzes the oxygenation of arachidonic acid at the 12 and 15 positions to form 12- and 15-hydroxyeicosatetraenoic acid (HETE), respectively, in an ∼6:1 ratio ([@B7]). Global *Alox15^−/−^* mice are protected from diabetes in response to low-dose streptozotocin (STZ) ([@B8]), and *Alox15^−/−^* mice on the nonobese diabetic (NOD) background are protected from the development of T1D in this model ([@B9]). Despite a central role for the adaptive immune system in the inflammation associated with T1D, studies have suggested that the primary site of action of 12/15-LOX in conferring T1D risk may be in infiltrating macrophages and the β-cell itself, where it promotes oxidative and endoplasmic reticulum stress ([@B10]). Accordingly, we have shown that pancreas-specific *Alox15* knockout mice are protected from diabetes in the low-dose STZ model of T1D, raising the possibility that loss of 12/15-LOX in β-cells may be sufficient to prevent hyperglycemia in T1D, despite the continued presence of the enzyme in macrophages ([@B11]).

Apart from its role in T1D pathogenesis, 12/15-LOX and its lipid products (e.g., 12-HETE) have also been implicated in a variety of other inflammatory diseases, including obesity and insulin resistance ([@B11]--[@B13]), cardiovascular disease ([@B14],[@B15]), and stroke ([@B16],[@B17]), as well as in neurodegenerative diseases ([@B18],[@B19]). Therefore, the development of specific 12/15-LOX inhibitors would have utility across a range of disorders. The absence of such specific and potent inhibitors of the LOX enzymes led members of our group to perform high-throughput screening to identify novel small-molecule inhibitors ([@B20]--[@B23]). Some of these inhibitors specifically protected β-cell lines and primary mouse and human islets from proinflammatory cytokine-induced dysfunction and death ([@B24],[@B25]), but to date, none have been tested in models of diabetes in vivo. ML351 is a small-molecule inhibitor of 12/15-LOX with high potency and selectivity versus other LOX and cyclooxygenase enzymes ([@B16],[@B17]). We sought to determine the efficacy of ML351 in models of T1D in vitro and in vivo, with a focus on its effects in islets.

Research Design and Methods {#s2}
===========================

Cells, Animals, and Assays {#s3}
--------------------------

Mouse βTC3 β-cells were cultured and maintained as previously described ([@B26]). Mouse islets were isolated from collagenase-perfused pancreata as previously described ([@B27]), and human islets were obtained from the Integrated Islet Distribution Program. Cell cultures were treated with a cytokine cocktail containing 5 ng/mL interleukin-1β, 10 ng/mL tumor necrosis factor-α, and 100 ng/mL interferon-γ and/or with ML351 for 24 h. Caspase-3 activation assay was performed by using the Apo-ONE Homogeneous Caspase-3/7 Assay (Promega). Static glucose-stimulated insulin secretion (GSIS) assays and immunostaining for reactive oxygen species (ROS) with CellROX (Invitrogen) were performed as previously described ([@B11]).

Male C57BL/6J mice and female NOD/ShiLTJ (NOD) mice were purchased from The Jackson Laboratory. Female CD1 mice were purchased from Charles River Laboratories. Mice were maintained at the Indiana University vivarium according to protocols approved by the institutional animal care and use committee. Mice were injected intraperitoneally (IP) daily with ML351 dissolved in 80:17:3 PBS:cremophor:ethanol or vehicle alone. Glucose measurements and IP glucose tolerance tests (GTTs) were performed as described ([@B28]). Mice were euthanized, serum/pancreata harvested, and insulin measured as previously described ([@B28]).

Pharmacokinetic Analyses {#s4}
------------------------

ML351 was synthesized as described previously ([@B23]). ML351 was quantified in plasma and tissue by high-performance liquid chromatography-tandem mass spectrometry (AB SCIEX QTRAP 5500) by using temazepam as the internal standard. Pharmacokinetic parameters for ML351, including area under the curve (AUC) and t~1/2~, were estimated by using noncompartmental methods. The maximum plasma concentration (C~max~) and time of C~max~ (t~max~) were obtained from the data. The AUC from 0 to infinity (AUC~0-∞~) was estimated from the AUC~0-t~ (time zero to the last quantifiable concentration \[C~last~\]) and the AUC from C~last~ to infinity C~last~/k~el~, where k~el~ is the rate constant of elimination.

Immunohistochemistry and Immunofluorescence {#s5}
-------------------------------------------

Pancreata were fixed and immunostained as previously described ([@B29]) by using the antibodies indicated in [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0215/-/DC1). 4-Hydroxynonenal (4-HNE) and glutathione peroxidase (GPX1) immunostainings were quantified by measuring pixel density per insulin-positive cell. Nrf2 was quantified by measuring nuclear and cytoplasmic pixel density per insulin-positive cell. Images were acquired with an LSM 700 confocal microscope (Zeiss). β-Cell mass and insulitis were calculated and scored from immunohistochemical staining as described previously ([@B28],[@B30]) by using at least three pancreas sections 70 μm apart from five mice per group.

Docking of LOX Inhibitors to the Human Proteome {#s6}
-----------------------------------------------

Fragment-based flexible docking method CANDOCK ([@B31]) was used to compute compound-proteome interaction signatures of the LOX inhibitors ML127 and ML351 with the human proteome, as done previously ([@B31]--[@B34]). Compound-proteome interaction scores of ML127 and ML351 were obtained with ∼50% of the human proteome (14,595 human proteins) consisting of previously selected experimental and computationally modeled protein structures ([@B31],[@B33],[@B34]), where docking was done with only the flexibility of small molecules and not the proteins with default CANDOCK parameters. A total of 5,423 human proteins was also annotated into druggable protein classes ([@B33]) to predict toxicity of ML127 and ML351.

RNA Sequencing Analysis {#s7}
-----------------------

RNA from treated islets (four biologic replicates per condition) was isolated with RNeasy Mini Kit (QIAGEN) and used to prepare a dual-indexed nonstranded cDNA library by using a SMART-Seq v4 Ultra Low Input RNA Kit (Clontech). Libraries were sequenced with a HiSeq 4000 system (Illumina). All sequenced libraries were mapped to the mouse genome (University of California, Santa Cruz, Genome Browser assembly ID mm10) by using STAR RNA-seq aligner ([@B35]). The reads distribution across the genome was assessed by bamutils (from NGSUtils) ([@B36]). Uniquely mapped sequencing reads were assigned to mm10 refGene genes through featureCounts (from Subread) ([@B37]). Data were normalized by using the trimmed mean of M values method. Differential expression analysis was performed by DESeq2 ([@B38]). The Benjamini-Hochberg procedure was used to adjust *P* values for multiple hypothesis testing. For volcano plots, the fold change (log~2~ scale) differences in genes between groups were plotted on the *x*-axis, and the *P* values (--log~10~ scale) were plotted on the *y*-axis by using R (version 3.2) and the ggplot2 package (version 2.2.1). Gene ontology enrichments (enrichGO, Biological Processes) were performed by using the R package clusterProfiler (version 3.4.4, Bioconductor) ([@B39]).

Statistical Analysis {#s8}
--------------------

All data are presented as the mean ± SEM. One-way ANOVA (with Dunnett posttest) was used for comparisons involving more than two conditions, and a two-tailed Student *t* test was used for comparisons involving two conditions. Prism 7 software (GraphPad) was used for all statistical analyses. Statistical significance was assumed at *P* \< 0.05.

Results {#s9}
=======

Effects of LOX Inhibitors on Cell Viability {#s10}
-------------------------------------------

Several potent small-molecule inhibitors of human 12-LOX and 15-LOX enzymes were identified through quantitative high-throughput screening ([@B20]--[@B22],[@B24]). Not previously tested was compound ML351, a mixed inhibitor that displayed nanomolar potency (IC~50~ ∼200 nmol/L) against human 15-LOX ([@B23]). We first tested the effect of ML351 on cell apoptosis in mouse islets ([Fig. 1*A*](#F1){ref-type="fig"}) and compared its effects with that of a related 12/15-LOX inhibitor, ML127 ([Fig. 1*B*](#F1){ref-type="fig"}). As shown in [Fig. 1*A* and *B*](#F1){ref-type="fig"}, ML351 displayed no deleterious effects on cellular apoptosis (by caspase activity assay) in the range between 1 and 50 μmol/L, whereas apoptosis was evident with ML127 at a concentration of 50 μmol/L ([Fig. 1*B*](#F1){ref-type="fig"}). These studies suggest that ML127 exhibits greater cellular toxicity than ML351.

![Toxicity of 12/15-LOX inhibitors in mouse islets. *A*: Chemical structure of ML351 and caspase activity measurements performed with mouse islets in the presence of varying doses of ML351 for 24 h. *B*: Chemical structure of ML127 and caspase activity measurements performed with mouse islets in the presence of varying doses of ML127 for 24 h. *C*: Distribution of CANDOCK scores with the number of human proteins predicted to bind to ML127 and ML351. Scores less than a cutoff of −39.13 are predicted strong binders for both compounds. *D*: Number of predicted strong binders for ML127 and ML351 distribution in eight druggable protein classes. *E*: 12-HETE levels in media from mouse islets incubated with the indicated concentrations of ML351 and proinflammatory cytokines for 4 h. Data are mean ± SEM (*n* = 3 independent experiments). \**P* \< 0.05 for the comparisons indicated. GPCR, G-protein--coupled receptor; RFU, relative fluorescence unit.](db170215f1){#F1}

Because toxicity often is related to off-target effects, we performed docking in silico of these inhibitors with ∼50% of the human proteome (14,595 proteins). We restricted the analysis to the human proteome because comprehensive structural data for the mouse proteome are unavailable. As shown in [Fig. 1*C*](#F1){ref-type="fig"}, ML127 has a significantly lower distribution of scores than ML351 (Kolmogorov-Smirnov test with *P* \< 2.2e-16), suggesting that ML127 is a stronger interactor with non-LOX proteins (lower score = stronger interaction). By using a binding score of −39.13 (the score for the binding of ML127 to human 15-LOX, the ortholog of mouse 12/15-LOX) as a cutoff to predict off-target interactions, we identified 4,115 interacting proteins for ML127 and only 843 interacting proteins for ML351 ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0215/-/DC1) shows a complete list of scores). We separated the selected binders into druggable classes (channels, G-protein--coupled receptors, kinases, ligases, nuclear receptors, proteases, phosphatases, transporters). As shown in [Fig. 1*D*](#F1){ref-type="fig"}, ML127 is predicted to bind to a substantially larger number of proteins than ML351, providing a possible explanation for its increased toxicity. We next tested the ability of ML351 to inhibit 12-HETE production in mouse islets. As shown in [Fig. 1*E*](#F1){ref-type="fig"}, ML351 decreased 12-HETE release into islet medium at a dose of 10 μmol/L, but this effect was unexpectedly not observed at 50 μmol/L.

Effects and Mechanisms of ML351 on Cytokine-Induced Islet Dysfunction {#s11}
---------------------------------------------------------------------

To determine whether ML351 protects mouse islets in a T1D model in vitro, we performed coincubation experiments by using ML351 and proinflammatory cytokines (interleukin-1β, tumor necrosis factor-α, interferon-γ) ([@B40]) and measured GSIS. Compared with untreated islets, islets exposed to proinflammatory cytokines for 24 h exhibited increased insulin release at 2.5 mmol/L glucose (evidence of degranulation) and impaired insulin release in response to 25 mmol/L glucose ([Fig. 2*A*](#F2){ref-type="fig"}). However, concurrent treatment with 10 μmol/L ML351 restored insulin secretion at 2.5 mmol/L glucose to control levels, and insulin release in response to 25 mmol/L glucose was significantly improved compared with treatment with proinflammatory cytokines alone ([Fig. 2*A*](#F2){ref-type="fig"}). This protective effect can still be seen to a lesser extent with 1 μmol/L drug but is lost at 50 μmol/L (a dose at which no reduction in 12-HETE was observed) and when the effect of ML351 is bypassed by the addition of 100 nmol/L 12-HETE ([Fig. 2*A*](#F2){ref-type="fig"}). The differences seen in GSIS assays were not caused by significant differences in total insulin content in islets ([Fig. 2*B*](#F2){ref-type="fig"}).

![12/15-LOX inhibition protects against cytokine-induced islet dysfunction and oxidative stress. *A*: Mouse islets were incubated for 24 h with cytokines, ML351, and 12-HETE before exposure to low (2.5 mmol/L) and high (25 mmol/L) glucose, after which insulin levels in the medium were measured (*n* = 3--4 independent experiments). \**P* \< 0.05 compared with control conditions (no cytokines, no ML351, no 12-HETE). *B*: Total islet insulin content for the insulin release experiments shown in *A*. *C*: Volcano plot of RNA sequencing analysis of mouse islets treated with cytokines + 10 μmol/L ML351 vs. cytokines alone for 24 h (*n* = 3 independent experiments; red, genes significantly altered \[*P* \< 0.05\]; yellow, genes altered more than twofold; green, genes significantly altered more than twofold). *D*: Gene ontology pathway analysis of data shown in *C*. *E*: βTC3 β-cells were transfected with Nrf2-Luc reporter and incubated with ML351 at the concentrations indicated and then treated for 6 h with cytokine before luciferase activity measurement (*n* = 10 independent experiments). Data are luciferase activity normalized to control conditions (no cytokines, no ML351). \**P* \< 0.05 compared with untreated control (no cytokines, no ML351). \#*P* \< 0.05 compared with cytokine treatment alone (no ML351). *F*: Mouse islets stained for ROS (CellROX reagent) (red) and DAPI (blue) upon treatment with or without cytokines and 10 μmol/L ML351. *G*: Human islets stained for ROS (CellROX reagent) (red) and DAPI (blue) upon treatment with or without cytokines and 10 μmol/L ML355. Original magnification ×200; scale bars = 100 μm. Bar graphs show quantitation of CellROX intensity in 10--16 islets from three independent mouse islet preparations (or human donors). \**P* \< 0.05 compared with untreated islets (no cytokines, no ML compound). Data are mean ± SEM. PIC, proinflammatory cytokines.](db170215f2){#F2}

To clarify the mechanism underlying the protective effects of ML351, we performed RNA sequencing analysis of islets treated with and without cytokines and with and without 10 μmol/L ML351. Principal component analysis showed distinct sample group clustering in the absence/presence of cytokines, with the addition of ML351 having less-pronounced effects than cytokines ([Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0215/-/DC1)). When comparing the effect of ML351 in the presence of cytokines (by using false discovery rate \<0.05 and fold change \>2.0) ([Fig. 2*C*](#F2){ref-type="fig"}), we found enrichment for genes corresponding to pathways responsive to extracellular signals, metabolism, and oxidative stress ([Fig. 2*D*](#F2){ref-type="fig"}). [Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0215/-/DC1) lists all significantly altered genes.

Previously, we demonstrated that 12-HETE inhibits the nuclear translocation of the antioxidant transcription factor Nrf2 ([@B11]). As a readout of antioxidant activity in β-cells, we examined both an Nrf2 response element reporter in β-cell lines and ROS production in primary islets in response to ML351 treatment. As shown in [Fig. 2*E*](#F2){ref-type="fig"}, when βTC3 cells transfected with the Nrf2 response element reporter were treated with 10 μmol/L ML351, no significant change in luciferase reporter activity was observed. When cells were treated with cytokines alone, a significant increase in luciferase activity was seen, which was increased further upon treatment with increasing doses of ML351 from 1 to 30 μmol/L. In accordance with the Nrf2 responses seen in the βTC3 cells, [Fig. 2*F*](#F2){ref-type="fig"} shows that ML351 reversed the stimulation of ROS production in mouse islets in response to proinflammatory cytokines in vitro. A similar effect was observed in human islets treated with the human-specific 12-LOX inhibitor ML355 ([Fig. 2*G*](#F2){ref-type="fig"}). Together, these results are consistent with an intracellular reduction in ROS in response to ML351 treatment.

ML351 Protects Against STZ-Induced Diabetes in Mice {#s12}
---------------------------------------------------

In pharmacokinetic studies in C57BL/6J mice, we analyzed the clearance of ML351 from the circulation tissues after IP and per os (PO) administration at 48 mg/kg (a dose previously used in mouse models of stroke) ([@B16],[@B17]). Higher plasma and tissue levels (C~max~) of ML351 were achieved after IP dosing than after PO dosing, and among the tissues analyzed (brain, fat, liver, pancreas), the drug preferentially distributed to fat ([Table 1](#T1){ref-type="table"}). Relatively greater distribution into pancreas was achieved after IP injection compared with PO delivery; therefore, we elected to pursue IP dosing for our models of diabetes in vivo.

###### 

Pharmacokinetic properties of ML351 in C57BL/6J mice

  Tissue         C~max~  (ng/mL or ng/g)[\*](#t1n1){ref-type="table-fn"}   t~max~ (h)   AUC~0-∞~  (ng/mL ⋅ h or ng/g ⋅ h)   t~1/2~ (h)
  -------------- --------------------------------------------------------- ------------ ----------------------------------- ------------
  IP injection                                                                                                              
   Plasma        454                                                       1            1,106                               9.4
   Brain         119                                                       4            1,573                               5.2
   Fat           5,293                                                     4            67,798                              4.6
   Liver         131                                                       4            1,837                               6.2
   Pancreas      255                                                       4            3,199                               4.1
  PO delivery                                                                                                               
   Plasma        135                                                       1            698                                 21.4
   Brain         159                                                       4            1,941                               3.3
   Fat           620                                                       4            7,835                               4.3
   Liver         157                                                       4            1,911                               3.1
   Pancreas      57                                                        4            700                                 3.4

\*Data units presented as nanograms per milliliter plasma or nanograms/gram tissue weight.

We next asked whether ML351 protects against diabetes development in an STZ β-cell injury model that mimics the inflammation seen in T1D. C57BL/6J mice were administered five daily low doses of STZ, after which they were followed for the development of diabetes. In addition, mice were injected daily with a range of ML351 concentrations (0 \[M0\], 10 \[M10\], 24 \[M24\], or 48 \[M48\] mg/kg) starting 5 days before the beginning of the STZ series and concluding 5 days after the last dose of STZ ([Fig. 3*A*](#F3){ref-type="fig"}). As shown in [Fig. 3*B*](#F3){ref-type="fig"}, nanomolar levels of drug were measurable in plasma just before STZ; these levels directly correlated with the dosages administered. Animals that received STZ had significant reductions in weight compared with the no-STZ controls ([Fig. 3*C*](#F3){ref-type="fig"}). However, at the end of the study, animals receiving STZ + M10 or STZ + M24 showed significantly less weight reduction than STZ + M0 animals; unexpectedly, the body weights of STZ + M48 animals resembled that of the STZ + M0 controls ([Fig. 3*C*](#F3){ref-type="fig"}). Moreover, these two treatment groups (STZ + M0 and STZ + M48) exhibited frank hyperglycemia by day 9 of the study ([Fig. 3*D*](#F3){ref-type="fig"}) and significantly impaired GTTs ([Fig. 3*E* and *F*](#F3){ref-type="fig"}). By contrast, animals administered STZ + M10 and STZ + M24 showed almost complete protection from hyperglycemia ([Fig. 3*D*](#F3){ref-type="fig"}), and their GTTs were indistinguishable from animals not receiving STZ or animals receiving ML351 only (M10 or M48) ([Fig. 3*E* and *F*](#F3){ref-type="fig"}). The improvement in glycemic control in the STZ + M10 animals was accompanied by improvements in GSIS in vivo ([Fig. 3*G*](#F3){ref-type="fig"}). Although STZ treatment led to slight worsening of insulin tolerance compared with animals not receiving STZ, the addition of ML351 did not affect peripheral glucose utilization response to insulin in insulin tolerance tests (ITTs) ([Fig. 3*H* and *I*](#F3){ref-type="fig"}).

![12/15-LOX inhibition protects against glycemic deterioration after multiple low-dose STZ injections. Nine-week-old male C57BL/6J mice were treated with vehicle or ML351. Multiple low-dose STZ injections (55 mg/kg) were given for 5 days (*n* = 5--15). *A*: Study design. *B*: Serum drug levels. *C*: Change in body weight from the start of the study. *D*: Random fed blood glucose measurements performed throughout the study. *E*: Results of GTTs performed at day 8. *F*: AUC from GTTs presented in *E*. *G*: GSIS in vivo. *H*: Results of ITTs performed at day 18. *I*: Area over the curve (AOC) from ITTs presented in *H*. Data are mean ± SEM. \**P* \< 0.05 compared with no-STZ + M0. \#*P* \< 0.05 compared with STZ + M0.](db170215f3){#F3}

ML351 Preserves β-Cell Mass and Attenuates STZ-Induced Oxidative Stress {#s13}
-----------------------------------------------------------------------

As shown in representative images in [Fig. 4*A*](#F4){ref-type="fig"}, islets of STZ + M0 and STZ + M48 animals were significantly reduced in size compared with non-STZ--treated controls, whereas STZ + M10 animals had islets that were indistinguishable from controls. Quantitative analysis of β-cell mass ([Fig. 4*B*](#F4){ref-type="fig"}) demonstrated that the animals receiving STZ + M0 and STZ + M48 had statistically significantly reduced mass compared with non-STZ--treated controls, whereas animals in the STZ + M10 and STZ + M24 groups maintained statistically normal mass. Consistent with the β-cell mass findings, random insulin levels were reduced in the STZ + M0 and STZ + M48 groups compared with non-STZ--treated controls but were preserved in the animals receiving the lower doses of ML351 ([Fig. 4*C*](#F4){ref-type="fig"}). Together, these data suggest that the lower doses of ML351 (10 and 24 mg/kg) protect β-cells from STZ.

![Effect of 12/15-LOX inhibition on β-cell mass and serum insulin in the multiple low-dose STZ diabetes mouse model. Nine-week-old male C57BL/6J mice were treated with vehicle or ML351. Multiple low-dose STZ injections (55 mg/kg) were given for 5 days (*n* = 5--15). *A*: Representative images of pancreata immunostained for insulin (brown) and counterstained for hematoxylin (blue). Original magnification ×100; scale bars = 200 μm. *B*: β-Cell mass of pancreata harvested at day 21. *C*: Random fed serum insulin levels. Data are mean ± SEM. \**P* \< 0.05 compared with no-STZ + M0.](db170215f4){#F4}

The deleterious effects of 12-HETE are likely partly due to its inhibition of Nrf2-mediated transcription of antioxidant genes ([@B11],[@B41]). We next immunostained pancreas tissues from STZ-treated and control animals for a marker of oxidative stress and for Nrf2. As shown in [Fig. 5*A*](#F5){ref-type="fig"}, the remaining β-cells in mice treated with STZ + M0 exhibited a significant increase in 4-HNE staining, a marker of oxidative stress ([@B11]). In contrast, 4-HNE staining was reduced to control levels in STZ + M10 and STZ + M24 mice. The increased 4-HNE staining seen in STZ + M0 mice correlated with a statistically significant decrease in Nrf2 nuclear localization in β-cells, a finding that was slightly, but significantly, reversed in STZ + M10 and STZ + M24 mice ([Fig. 5*B*](#F5){ref-type="fig"}). Immunostaining for GPX1, a target of Nrf2 activation, was accordingly decreased in β-cells of STZ + M0 mice but rescued to control levels in STZ + M24 and STZ + M10 mice ([Fig. 5*C*](#F5){ref-type="fig"}).

![Inhibition of 12/15-LOX protects against islet oxidative stress in the multiple low-dose STZ diabetes mouse model. Nine-week-old male C57BL/6J mice were treated with vehicle or ML351. Multiple low-dose STZ injections (55 mg/kg) were given for 5 days (*n* = 5--15). Fixed pancreatic sections were subjected to immunofluorescence staining. Shown are representative images and the pixel density or nuclear/cytoplasmic ratio from analysis of at least three animals per group. *A*: Oxidative stress marker 4-HNE (magenta), insulin (green), and DAPI (blue). *B*: Nrf2 (magenta), insulin (green), and DAPI (blue). *C*: Antioxidant enzyme GPX1 (magenta), insulin (green), and DAPI (blue). Original magnification ×200; scale bars = 50 μm. \**P* \< 0.05 compared with no-STZ + M0.](db170215f5){#F5}

ML351 Protects Against Early Glycemic Deterioration in NOD Mice {#s14}
---------------------------------------------------------------

Female NOD mice develop spontaneous autoimmune diabetes between 12 and 24 weeks of age ([@B5],[@B30]). A prelude to the development of diabetes in this model is β-cell dysfunction and consequent dysglycemia, which are evident as early as 6 weeks of age ([@B5],[@B42]). To assess whether pharmacologic inhibition of 12/15-LOX protects against the early glycemic deterioration characteristic of this model, we administered 24 mg/kg of ML351 (M24) or vehicle (M0) by IP injection daily to female NOD mice beginning at 6 weeks of age for 2 weeks and then assessed glycemic control at 8 weeks of age; for comparison of the effects of the drug on a nondiabetes-prone strain, CD1 mice (an outbred strain closely related to NOD mice) were treated in parallel. Although fed blood glucose values at 8 weeks of age showed no differences between treated and untreated animals of either strain ([Fig. 6*A*](#F6){ref-type="fig"}), GTTs showed that NOD + M24 animals exhibited improved glycemic control compared with NOD + M0 animals ([Fig. 6*B* and *C*](#F6){ref-type="fig"}). CD1 + M0 and CD1 + M24 animals exhibited indistinguishable GTTs, suggesting that the drug had no effect on this strain ([Fig. 6*B* and *C*](#F6){ref-type="fig"}). Analysis of pancreas from mice ([Fig. 6*D*](#F6){ref-type="fig"}) revealed that β-cell mass was unaffected by administration of ML351 in either strain ([Fig. 6*E*](#F6){ref-type="fig"}), signifying an effect of the drug on β-cell function in NOD animals. Consistent with improved β-cell function, a significant reduction in insulitis ([Fig. 6*D*](#F6){ref-type="fig"}) and mean insulitis score ([Fig. 6*F*](#F6){ref-type="fig"}) was observed in NOD + M24 mice compared with NOD + M0 controls. Because insulitis is characterized by macrophages in early prediabetic NOD mice ([@B43]) and 12/15-LOX is also expressed in macrophages, we asked whether ML351 treatment affected the prevalence of anti-inflammatory, galectin 3--positive macrophages in the infiltrate ([@B44]). As shown in [Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db17-0215/-/DC1), the insulitic infiltrate of NOD + M24 animals had a significantly greater percentage of galectin 3--positive macrophages than NOD + M0 animals.

![12/15-LOX inhibition mitigates glycemic deterioration in prediabetic NOD mice. Six-week-old NOD and CD1 female mice were injected daily for 2 weeks with vehicle or 24 mg/kg ML351 (*n* = 5). *A*: GTTs performed at 8 weeks of age. *B*: AUC of GTTs presented in *A*. *C*: Random fed blood glucose at 8 weeks of age. *D*: Representative images of pancreata immunostained for insulin (brown) and counterstained with hematoxylin (blue) from prediabetic 8-week-old mice. Original magnification ×100; scale bars = 100 μm. *E*: β-Cell mass of pancreata harvested at week 8. *F*: Average insulitis score. *G*: Representative images of pancreata immunostained for glucagon (magenta), insulin (green), and DAPI (gray). Original magnification ×200; scale bars = 100 μm. \**P* \< 0.05 compared with CD1 + M0. \#*P* \< 0.05 compared with NOD + M0. INS, insulin; NS, not significant.](db170215f6){#F6}

Finally, we examined pancreatic tissue from CD1 and NOD mice for the presence of oxidative stress. β-Cells from NOD + M24 mice showed protection against oxidative stress (4-HNE staining) compared with NOD + M0 controls ([Fig. 7*A*](#F7){ref-type="fig"}). This finding in NOD + M24 animals was consistent with increased β-cell Nrf2 nuclear localization ([Fig. 7*B*](#F7){ref-type="fig"}) and increased GPX1 immunoreactivity ([Fig. 7*C*](#F7){ref-type="fig"}) compared with NOD + M0 animals. ML351 had no effect on any of these parameters in CD1 mice ([Fig. 7*A*--*C*](#F7){ref-type="fig"}).

![12/15-LOX inhibition reduces islet oxidative stress in prediabetic NOD mice. Fixed pancreatic sections from CD1 and NOD mice treated with vehicle or 24 mg/kg ML351 were subjected to immunofluorescence staining. Shown are representative images and the pixel density or nuclear/cytoplasmic ratio from analysis of at least three animals per group. *A*: Oxidative stress marker 4-HNE (magenta), insulin (green), and DAPI (blue). *B*: Nrf2 (magenta), insulin (green), and DAPI (blue). *C*: Antioxidant enzyme GPX1 (magenta), insulin (green), and DAPI (blue). Original magnification ×200; scale bars = 100 μm. \**P* \< 0.05 compared with CD1 + M0.](db170215f7){#F7}

Discussion {#s15}
==========

The LOXs catalyze oxygenation of polyunsaturated fatty acids to form hydroperoxy fatty acids (e.g., 12-HETE) that generate ROS ([@B45],[@B46]). In mice, 12/15-LOX, encoded by *Alox15*, contributes negatively to β-cell function ([@B8],[@B11],[@B12],[@B47],[@B48]), and the human 12-LOX enzyme levels are increased in islets of humans with T1D ([@B49]). Notwithstanding its potential role in T1D pathogenesis, no genetic variants of the LOX enzymes in humans have been closely linked to susceptibility for T1D ([@B50]). Nevertheless, given their pervasive roles in many diseases, the LOXs have been prime targets for the development of small-molecule inhibitors. Early attempts to develop 12/15-LOX inhibitors met with limited success, with molecules lacking tight specificity, chemical tractability, or other drug-like properties. More recently, high-throughput screening of small-molecule drug libraries followed by chemical optimization have resulted in a series of compounds with nanomolar potency against 12/15-LOX ([@B17],[@B23],[@B51]). Studies of ML127 have shown promising results in blocking 12-HETE production in human and mouse islets ([@B24]). Here, we show that ML127 exhibits cytotoxicity at higher doses. By contrast, ML351 showed negligible cytotoxicity in vitro. These findings might be explained by off-target interactions, as predicted by computational docking to the human proteome. On the basis of these findings, we pursued ML351 as a prime candidate for 12/15-LOX inhibition in vitro and in vivo.

12-HETE functions as a proinflammatory lipid mediator ([@B47],[@B48]) that increases cellular ROS either directly or through signaling through the putative receptor Gpr31 ([@B52]). Consistent with inhibiting 12/15-LOX, ML351 exposure led to reduced 12-HETE release from mouse islets, reduced ROS generation in islets exposed to proinflammatory cytokines, and affected gene pathways involved in hypoxia, cellular death, and the antioxidant response. Although we did not see direct effects on genes involved in the endoplasmic reticulum stress pathway (a response that 12/15-LOX promotes \[[@B11],[@B53]\]), these gene expression events likely occur later than the 24-h time point we examined in vitro ([@B5]).

To translate these studies to mouse models of diabetes, we performed pharmacokinetic studies and found that ML351 achieves penetrance in key metabolically active tissues after both IP and PO administration. We initially used a low-dose STZ mouse model of T1D in which low-level β-cell death induced by the alkylating effect of STZ leads to the influx of inflammatory cells (e.g., macrophages) and the subsequent local release of proinflammatory cytokines ([@B28],[@B54],[@B55]). In this context, the current studies show that ML351 prevents β-cell oxidative stress, β-cell dysfunction, and hyperglycemia in treated mice. Of note, a higher dose of ML351 (48 mg/kg) had no protective effect. Although this finding indicates an independent toxic effect of ML351 at higher doses, this seems unlikely because the mice treated with 48 mg/kg alone showed normoglycemia. The current studies of ML351 in vitro, wherein higher doses of the drug (50 μmol/L) failed to inhibit 12-HETE production or reverse cytokine effects on GSIS, raise the likely possibility that aggressive inhibition of 12/15-LOX at high doses of ML351 causes compensatory activity of another LOX isoform (12-LOX) to generate 12-HETE.

In prior studies, we showed an effect of 12-HETE in inhibiting the nuclear translocation of Nrf2, thereby preventing its consequent transcription of genes encoding antioxidant enzymes ([@B11]). We show in the current study that ML351 also enhances activity of an Nrf2 reporter in cell lines and promotes nuclear translocation of Nrf2 and activation of GPX1 in β-cells of STZ-treated mice. Given the similarity of these pharmacologic studies to our earlier pancreas-specific knockout studies of *Alox15* ([@B11]), ML351 possibly inhibited 12/15-LOX directly in β-cells. However, we cannot rule out that inhibition of 12/15-LOX in macrophages may have also contributed to the β-cell--protective effect in this model. Given the relative scarcity of macrophage infiltration in the STZ model ([@B54]), quantitative assessment of the effects of ML351 on macrophages is difficult. In this regard, the NOD model provides more insight. Treatment of NOD mice with ML351 led to improved glycemic control and significantly reduced insulitis. The reduction of β-cell death in NOD mice has been suggested to lead to reductions in insulitis, likely by mitigating the chemotactic signals released by dying β-cells ([@B4],[@B5]). On the other hand, we observed that galectin 3--positive anti-inflammatory macrophages make up a greater percentage of the insulitic infiltrate, which points to a possible direct effect of the drug on macrophages. In this regard, ROS has been proposed as an important mediator of immune cell pathogenicity that allows for initiation and propagation of insulitis ([@B56]). Treatment with ML351, therefore, may mitigate insulitis by reducing ROS production in innate and adaptive immune cells.

Although this study is an important first step toward the translation of a new drug class for the prevention of diabetes, significant hurdles remain. Whereas the LOXs are structurally homologous between mice and humans, differences in function and spatial expression of LOXs exist between the species. As noted, the LOX encoded by *Alox15* is the primary LOX expressed in mouse β-cells and macrophages, whereas in humans this LOX is encoded by *ALOX12.* In biochemical studies, ML351 demonstrated \>250-fold selectivity for the human LOX encoded by *ALOX15* versus *ALOX12* ([@B23]). As such, ML351 would not be an ideal choice for targeting the relevant LOX in human β-cells and macrophages. Conversely, a related drug, ML355, exhibits selectivity for human LOX encoded by *ALOX12* ([@B21],[@B25]) and appears to have similar effects on reducing human islet ROS production (shown here). Unfortunately, ML355 cannot as yet be tested in preclinical models in vivo. This limitation to preclinical testing must await either the selection of a better model organism or the humanization of the mouse *Alox15* alleles. In the meantime, the studies presented here offer an important new insight into the feasibility of inhibiting 12/15-LOX for the prevention and treatment of T1D.
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